Antibody Production Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 12.16 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Antibody Production Market Analysis
COVID-19 had a significant impact on the antibody production market. The government-imposed lockdowns, supply chain disruption, and trade bans in several countries significantly reduced antibody production during the initial phase of the pandemic. However, the emergency use authorization (EUA) for monoclonal antibodies as a treatment against COVID-19 by healthcare organizations increased the demand for antibody production in the industry. For instance, the United States COVID-19 Treatment Panel recommended the use of monoclonal antibodies for treating the SARS-CoV-2 variants, such as Bebtelovimab 175 mg intravenous injections, Bamlanivimab, etesevimab, and a few others. Therefore, the demand for antibodies has been increasing in the past few years. The trend is expected to continue in the forecast period owing to the long-term impact of COVID-19 on a person's health.
The major factors for the growth of the antibody production market include the rising adoption of targeted immunotherapy, the increase in the R&D expenditure of pharmaceutical and biotechnology companies, and the rising demand for therapeutic antibodies.
Antibodies are used in the treatment of various diseases, such as cancer, rheumatoid arthritis, and other chronic diseases. The targeted therapy is attaining importance due to its specificity toward cancer cells while sparing the toxicity to off-target cells. As there is a rising prevalence of cancer, targeted therapies are getting more attention. For instance, as per the Australian Institute of Health and Welfare (AIHW) 2021 report, a total of 150,782 new cancer cases were estimated in Australia in 2021. Out of the total number of cancer cases, breast cancer cases were estimated to be 20,030, lung cancer with 13,810 new cases, and prostate cancer 18,110 cases were estimated to occur in 2021. Some examples of monoclonal antibodies used in targeted therapies are bevacizumab, cetuximab, and ipilimumab. Hence with the high burden of cancer, the antibody production market is estimated to grow during the forecast period.
The rising adoption of targeted therapies is expected to propel the overall growth of the antibody production market over the forecast period. The success rates and blockbuster sales of biologics have also made large pharmaceutical companies shift their presence to biopharma. Over the past two decades, the chimerization and humanization of mAbs (monoclonal antibodies) have led to the approval of several drugs & therapies for the treatment of autoimmune diseases, cancer, and transplant rejection. For instance, in August 2022, the FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable or metastatic HER2-low breast cancer. It is one of the first approved targeted therapy. Such approvals highlight the need and demand for the treatment of life-threatening diseases like breast cancer which is further expected to augment the market growth during the forecast period.
Therefore, owing to the factors such as the high prevalence of diseases requiring targeted therapies and rising product launches by key players, the studied market is anticipated to witness growth over the analysis period. However, the high cost involved in antibody production and stringent government regulations is expected to impede the growth of the market.
Antibody Production Market Trends
This section covers the major market trends shaping the Antibody Production Market according to our research experts:
The Monoclonal Antibodies Segment is Expected to Hold a Significant Market Share Over The Forecast Period
Monoclonal antibodies have large applications in diagnostics, therapeutics, and targeted drug delivery systems, not only for infectious diseases caused by bacteria, viruses, and protozoa but also for cancer, metabolic, and hormonal disorders.
The segment is expected to hold a significant market share during the forecast period, owing to the rising investment in monoclonal antibody research and an increase in antibody-based product launches. For instance, according to an article published in the Journal of Biomedical Sciences in January 2022, monoclonal antibodies (mAbs) emerged as powerful tools to treat and detect numerous diseases because of their high specificity and reliability. This characteristic has urged the demand for several research studies in which monoclonal antibodies were used for COVID-19 therapy and SARS-CoV-2 detection. Thus, the utility of monoclonal antibodies is immense, ranging from cancer to osteoporosis and organ transplant rejection, which is estimated to propel segment growth.
Furthermore, the strategic initiatives adopted by pharma and biotech companies, such as rising research and development leading to product approvals and launches and a growing collaboration to develop advanced monoclonal antibodies, are also fueling the segment growth. For instance, in May 2021, Cipla launched Roche's antibody cocktail (Casrivimab and Imdevimab) in India for the treatment of mild- to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kg). Additionally, global pharmaceutical companies are investing heavily in the R&D of cancer biologics drugs (monoclonal antibodies) because they are very efficient and non-toxic in the diagnostics and treatment of different types of cancer as compared to chemotherapy and other cancer treatment methods. These factors are expected to fuel the growth of the monoclonal antibodies segment in the coming years.
North America is Expected to Hold a Significant Market Share Over The Forecast Period
North America is expected to hold a significant share of antibody production owing to the high prevalence of cancer in the region and the strong presence of favorable healthcare infrastructure, and innovations and product launches by market players in the region.
According to the American Cancer Society Cancer Statistics 2022, 1,918,030 new cancer cases are predicted to occur in the United States in 2022. Out of the total cancer cases, breast cancer is estimated for 290,560 new cases, leukemia with 60,650 new cases, and lymphoma with 89,010 new cases in the United States in 2022. Additionally, according to the Canadian Cancer Statistics November 2021 report, an estimated 2 in 5 Canadians were likely to be diagnosed with cancer in their lifetime. It stated that an estimated 229,200 Canadians was predicted to be diagnosed with cancer in 2021.
Furthermore, there is a rise in the approval of antibodies for the treatment of cancer and various types of diseases, which is also contributing to the market growth in the region. For instance, in February 2022, the U.S. FDA issued an emergency use authorization (EUA) for a new monoclonal antibody for bebtelovimab used for the treatment of COVID-19 that retains activity against the omicron variant. The EUA was for the treatment of mild to moderate COVID-19 in adults and pediatric COVID-19-positive patients. The EUA for monoclonal antibodies is expected to create opportunities for pharmaceutical and biotechnology companies to expedite their research and development on the antibodies to develop an innovative treatment, thereby propelling market growth in the region.
Moreover, the antibody production expansion by key players in the region is also fuelling market growth. For instance, in July 2021, Cytiva and Pall Corporation signed a collaboration agreement for the expansion of manufacturing capacity and services across geographies to meet the growing demand for biotechnology solutions. Cytiva and Pall Corporation's capacity expansion will increase the manufacture of key products used to make biological medicines which are ultimately estimated to propel antibody production in the region during the forecast period.
Antibody Production Industry Overview
The antibody production market is consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known. Some key players in the global antibody production market are Danaher Corporation, Merck KGaA, Sartorius, Thermofisher Scientific, Eppendorf AG, INTEGRA Biosciences AG, Genetix Biotech Asia Pvt Ltd, Solaris Biotech, Grifols, F. Hoffmann-La Roche AG, and FiberCell Systems Inc.
Antibody Production Market Leaders
-
Sartorius AG
-
Danaher Corporation
-
Merck KGaA
-
Eppendorf AG
-
Thermo Fisher Scientific
*Disclaimer: Major Players sorted in no particular order
Antibody Production Market News
- July 2022: GigaGen Inc., a subsidiary of Grifols, published a research article in the international peer-reviewed journal Pathogens. The article showcased the GMP (good manufacturing practice) manufacturing and IND (Investigational New Drug)-enabling studies of its new class of drugs, recombinant polyclonal antibodies, describing the company's recombinant polyclonal product that targets SARS-CoV-2, GIGA-2050.
- June 2022: The National Institute of Health (NIH) of the United States launched a clinical trial testing for a monoclonal antibody, dupilumab, which can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighbourhoods.
Antibody Production Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Adoption of Targeted Immunotherapy
- 4.2.2 Increase in the R&D Expenditure of Pharmaceutical and Biotechnology Companies
- 4.2.3 Rising Demand for Therapeutic Antibodies
-
4.3 Market Restraints
- 4.3.1 High Costs Involved in the Antibody Production
- 4.3.2 Stringent Government Regulations
-
4.4 Porter Five Forces
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Antibody Type
- 5.1.1 Monoclonal Antibodies
- 5.1.2 Polyclonal Antibodies
- 5.1.3 Other Antibody Types
-
5.2 By Process
- 5.2.1 Upstream Processing
- 5.2.1.1 Bioreactors
- 5.2.1.2 Consumables
- 5.2.2 Downstream Processing
- 5.2.2.1 Chromatography Systems
- 5.2.2.2 Chromatography Resins
- 5.2.3 Filtration
-
5.3 By End User
- 5.3.1 Pharmaceutical and Biotechnology Companies
- 5.3.2 Research Laboratories
- 5.3.3 Other End Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Applikon Biotechnology Inc.
- 6.1.2 INTEGRA Biosciences AG
- 6.1.3 Danaher Corporation
- 6.1.4 Eppendorf AG
- 6.1.5 Genetix Biotech Asia Pvt Ltd
- 6.1.6 Merck KGaA
- 6.1.7 Sartorius AG
- 6.1.8 Solaris Biotech
- 6.1.9 Thermo Fisher Scientific Inc.
- 6.1.10 Grifols
- 6.1.11 F. Hoffmann-La Roche AG
- 6.1.12 FiberCell Systems Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAntibody Production Industry Segmentation
As per the scope of the report, antibody production refers to the process of creating a specific antibody. In a broad sense, it consists of various methods, such as upstream, downstream, and filtration. The process involves the preparation of antigen samples, which are injected into the laboratory or farm animals to evoke high expression levels of antigen-specific antibodies in the serum, which are then recovered from the animal. The Antibody Production Market is Segmented by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies, Other Antibody Types), Process (Upstream Processing, Downstream Processing, Filtration), End User (Pharmaceutical and Biotechnology Companies, Research Laboratories, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Antibody Type | Monoclonal Antibodies | |
| Polyclonal Antibodies | ||
| Other Antibody Types | ||
| By Process | Upstream Processing | Bioreactors |
| Consumables | ||
| By Process | Downstream Processing | Chromatography Systems |
| Chromatography Resins | ||
| By Process | Filtration | |
| By End User | Pharmaceutical and Biotechnology Companies | |
| Research Laboratories | ||
| Other End Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Antibody Production Market Research FAQs
What is the current Antibody Production Market size?
The Antibody Production Market is projected to register a CAGR of 12.16% during the forecast period (2024-2029)
Who are the key players in Antibody Production Market?
Sartorius AG, Danaher Corporation, Merck KGaA, Eppendorf AG and Thermo Fisher Scientific are the major companies operating in the Antibody Production Market.
Which is the fastest growing region in Antibody Production Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Antibody Production Market?
In 2024, the North America accounts for the largest market share in Antibody Production Market.
What years does this Antibody Production Market cover?
The report covers the Antibody Production Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Antibody Production Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Antibody Production Industry Report
Statistics for the 2024 Antibody Production market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Antibody Production analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
